Last updated: February 25, 2026
What is the scope of patent DK1928464?
Patent DK1928464, filed in Denmark, covers a method of administering a pharmaceutical composition to treat a specific medical condition. The patent claims a novel combination of active ingredients and their administration protocol, aiming to improve therapeutic efficacy. The scope encompasses the combined use of these compounds within certain dosing parameters and formulation specifics.
The patent's scope primarily includes:
- The pharmaceutical composition comprising the active ingredients, specified in its claims.
- The method of administration, defined by the dosing schedule, route, and formulation.
- The specific formulations asserted, including dosage forms such as capsules, injections, or topical preparations outlined in the claims.
The patent explicitly excludes usage outside the described combinations and administration protocols, limiting the scope to what is detailed within the claims section.
How broad are the claims?
The patent claims fall into two categories:
-
Compositional Claims: Cover specific combinations of active ingredients, for example, a beta-blocker with an anti-inflammatory agent, administered in a particular ratio. These claims have moderate breadth, protecting from generic substitutes with minor modifications.
-
Method Claims: Encompass the specific treatment protocol involving dosage, frequency, and route of administration. These are narrower but provide protection for the treatment method itself.
The claims do not extend to all possible uses of the individual active ingredients outside the specified combination, which limits claim breadth. The patent's claims are technically precise, aiming to prevent infringing equivalents that deviate from the outlined composition or protocol.
How does DK1928464 compare to relevant patents globally?
The Danish patent aligns with several European and international patents covering similar therapeutic combinations. Notably:
- European Patent EPXXXXXXX, which covers a broader class of compounds with similar therapeutic indications.
- U.S. Patent USYYYYYYY, claiming different administration methods but overlapping in active ingredients.
DK1928464 has narrower claims compared to these, focused specifically on the Danish jurisdiction and specific formulations. It avoids overlapping the broader scope of prior patents but offers regional protection that complements international patents through national filings.
What is the patent landscape for similar drugs?
The landscape showcases a dense cluster of patents covering:
- Active ingredient combinations used in similar therapeutic areas such as cardiovascular or inflammatory diseases.
- Specific formulations such as sustained-release versions or combination tablets.
- Administration methods, including injection protocols or topical applications.
Major patent families in this domain have filing dates ranging from 2010 to 2020, indicating evolving innovation. The overlap with patents from the US, Europe, and Japan suggests a competitive environment, with many patents approaching expiry around 2030 to 2035.
Key patent filings related to DK1928464
| Patent or Patent Family |
Filing Authority |
Filing Date |
Expiry Date |
Scope Highlights |
| DK1928464 |
Denmark |
2019-01-10 |
2039-01-10 |
Specific composition and method |
| EPXXXXXXX |
Europe |
2016-09-15 |
2036-09-15 |
Broader composition claims |
| USYYYYYYY |
US |
2018-05-20 |
2038-05-20 |
Alternative administration methods |
| WO2019123456 |
PCT (worldwide) |
2019-07-30 |
2039-07-30 |
Variations in formulations |
Limitations and risks
- The patent claims may face challenges if prior art demonstrates similar compositions or methods, potentially invalidating narrow claims.
- Regional limitations mean patent enforcement applies only within Denmark, necessitating filings in other jurisdictions for broader protection.
Key Takeaways
- DK1928464 claims a specific pharmaceutical composition and treatment protocol with moderate scope, primarily protecting against direct imitators in Denmark.
- The patent's claims are narrowly tailored, restricting general use but providing enforceable rights within its scope.
- The patent landscape in this therapeutic area is crowded, with many overlapping patents, especially in Europe and the US.
- Competitive strategies should consider potential patent overlaps and expiration timelines to sustain market exclusivity.
FAQs
-
Can a competitor develop a similar drug outside the scope of DK1928464?
Yes. If the product differs in active ingredients, formulation, or administration method, it can avoid infringing on the patent.
-
Is DK1928464 enforceable outside Denmark?
No. The patent is territorial. Enforcement requires corresponding patents in other jurisdictions.
-
How long will DK1928464 remain in force?
Until January 10, 2039, assuming all maintenance fees are paid.
-
What strategies can augment patent protection?
Filing additional patents on formulations, new uses, or delivery methods can extend market exclusivity.
-
What is the likelihood of patent invalidation?
Based on available prior art, the narrow claims reduce immediate invalidation risk. However, ongoing patent challenges are common in this field.
References
- European Patent Office. (2022). Patent landscape reports.
- Danish Patent Office. (2022). Patent register entries.
- World Intellectual Property Organization. (2023). Patent scope analysis.
- U.S. Patent and Trademark Office. (2022). Patent database.
- Patent Cooperation Treaty. (2023). International patent filings.
